The acute anticonvulsant effects of deoxycorticosterone in developing rats: Role of metabolites and mineralocorticoid-receptor responses

Epilepsia

Volumn 46, Issue 12, 2005, Pages 1888-1897

  Edwards, Heather E ^a   Vimal, Sutha ^a   Burnham, W McIntyre ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anticonvulsant; Corticosteroids; Development; Pentylenetetrazol

Indexed keywords

ALDOSTERONE; CORTICOSTEROID; CORTICOSTERONE; CORTICOTROPIN; DEOXYCORTICOSTERONE; DEXAMETHASONE; DIHYDRODEOXYCORTICOSTERONE; DRUG METABOLITE; FINASTERIDE; FLUDROCORTISONE; FLUTAMIDE; MEDROXYPROGESTERONE ACETATE; MINERALOCORTICOID RECEPTOR; PENTETRAZOLE; PROGESTERONE; PROGESTERONE RECEPTOR; SPIRONOLACTONE; TETRAHYDRODEOXYCORTICOSTERONE; 4 AMINOBUTYRIC ACID RECEPTOR; ALDOSTERONE ANTAGONIST; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; HORMONE RECEPTOR INTERACTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; METABOLITE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SEIZURE; SINGLE DRUG DOSE; STEROIDOGENESIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM;

ALDOSTERONE ANTAGONISTS; ANIMALS; ANIMALS, NEWBORN; ANTICONVULSANTS; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FINASTERIDE; PENTYLENETETRAZOLE; RATS; RECEPTORS, GABA; RECEPTORS, MINERALOCORTICOID; RECEPTORS, PROGESTERONE; SEIZURES; SPIRONOLACTONE;

EID: 33644807607     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00295.x     Document Type: Article

References (34)

1. Edwards HE, Vimal S, Burnham WM. Dose-, time-, age- and sexresponse profiles for the anticonvulsant effects of deoxycorticosterone in developing rats. Exp Neurol 2002;176:364-70.
2. Neugebauer R, Myunghee P, Hauser WA, et al. Stressful life events and seizure frequency in patients with epilepsy. Epilepsia 1994;35:336-43.
3. Stephen EHM, Noad KB. Status epilepticus occurring during cortisone therapy. Med J Aust 1951;8:334-5.
4. Arnold ST, Dodson WE. Epilepsy in children. Baillieres Clin Neurol 1996;5:783-2.
5. Scott RC, Neville BG. Pharmacological management of convulsive status epilepticus in children. Dev Med Child Neurol 1999;41:207-10.
6. Snead OC 3rd, Horton EJ. Treatment of neonatal seizures. Semin Neurol 1993;13:53-7.
7. Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505-11.
8. Roberts AJ, Keith LD. Mineralocorticoid receptors mediate the enhancing effects of corticosterone on convulsion susceptibility in mice. J Pharmacol Exp Ther 1994;270:505-11.
9. Reddy DS, Rogawski MA. Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci 2002;22:3795-805.
10. Roberts AJ, Crabbe JC, Keith LD. Type I corticosteroid receptors modulate PTZ-induced convulsions of withdrawal seizure prone mice. Brain Res 1993;626:143-8.
11. Edwards HE, Vimal S, Burnham WM. The Influence of ACTH and adrenocorticosteroids on seizure susceptibility in the developing male rat. Exp Neurol 2002;175:182-90.
12. Russel DW, Wilson JD. Steroid 5alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
13. Sakai RR, McEwen BS, Fluharty SJ, et al. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int 2000;57:1337-45.
14. Marks R, Barlow J, Funder JW. The mechanisms of steroid induced vasoconstriction: glucocorticoid antagonist studies. J Clin Endocrinol Metab 1982;54:1075-82.
15. Rupprecht R, Reul JMHM, Trapp T, et al. Progesterone receptor mediated effects of neurosteroids. Neuron 1993;11:523-30.
16. Celotti F, Negri-Cesi P, Poletti A. Steroid metabolism in the mammalian brain: 5alpha-reduction and aromatization. Brain Res Bull 1997;44:365-75.
17. Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med 1997;48:231-40.
18. Pavlides C, Watanabe Y, Magarinos AM, et al. Opposing roles of type I and type II adrenal steroid receptors in hippocampal long-term potentiation. Neuroscience 1995;68:387-94.
19. Azzolina B, Ellsworth K, Andersson S, et al. Inhibition of rat alpha-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition. J Steroid Biochem Mol Biol 1997;61:55-64.
20. Kokate TG, Cohen AL, Karp E, et al. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 1996;35:1049-56.
21. Lephart ED, Ladle DR, Jacobson NA, et al. Inhibition of brain 5 alpha-reductase in pregnant rats: effects on enzymatic and behavioral activity. Brain Res 1996;739:356-60.
22. Reul JM, van den Bosch FR, de Kloet ER. Differential response of type I and type II corticosteroid receptors to changes in plasma steroid level and circadian rhythmicity. Neuroendocrinology 1987;45:407-12.
23. Schmidt JB. Other antiandrogens. Dermatology 1998;196:153-7.
24. Kokate TG, Banks MK, Magee T, et al. Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999;288:679-84.
25. Baram TZ, Schultz L. Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Brain Res Dev Brain Res 1991;61:97-101.
26. Salmenpera M, Kahri A. Corticosterone, 18-OH-deoxycorticosterone, deoxycorticosterone and aldosterone secretion in tissue culture of foetal rat adrenals in the presence and the absence of ACTH. Acta Endocrinol 1976;83:781-93.
27. Edwards HE, Burnham WM, MacLusky NJ. Testosterone and its metabolites affect afterdischarge thresholds and the development of amygdala kindled seizures. Brain Res 1999;838:151-7.
28. Johnson JA, Davis JO, Taylor AA, et al. Secretion rates and plasma levels of deoxycorticosterone and removal rates of deoxycorticosterone and aldosterone in the pregnant dog. Endocrinology 1974;94:580-3.
29. Melcangi RC, Celotti F, Ballabio M, et al. Ontogenetic development of the 5 alpha-reductase in the rat brain: cerebral cortex, hypothalamus, purified myelin and isolated oligodendrocytes. Brain Res Dev Brain Res 1988;44:181-8.
30. Poletti A, Celotti F, Melcangi RC, et al. Kinetic properties of the 5 alpha-reductase of testosterone in the purified myelin, in the subcortical white matter and in the cerebral cortex of the male rat brain. J Steroid Biochem 1990;35:97-101.
31. Lu S, Simon NG, Wang Y, et al. Neural androgen receptor regulation: effects of androgen and antiandrogen. J Neurobiol 1999;41:505-12.
32. Sze PY, Towle AC. Developmental profile of glucocorticoid binding to synaptic plasma membrane from rat brain. Int J Dev Neurosci 1993;11:339-46.
33. Zemanova Z, Pacha J. Localization of Na,K-ATPase activity in developing rat distal colon: role of corticosteroids. Mech Ageing Dev 1998;101:129-43.
34. Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991;252:1848.